Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

APHA laboratories to gain £200m investment
APHA, an executive agency of Defra, works to protect the UK's livestock industry.
The upgrades will tackle dangerous animal diseases.

The UK’s main research and laboratory testing facility is to benefit from a £200 million investment to help maintain its scientific and veterinary capabilities.
 
The Animal and Plant Health Agency (APHA) laboratories in Weybridge will receive the investment as part of the government’s Plan for Change mission, which seeks to help protect the profits of farmers and other food producers.

From this investment, APHA plans to replace and upgrade its biosecurity facilities. This will increase the laboratory’s ability to detect and prevent disease outbreaks.

The boost will also enable the department to introduce a new science hub. The facility will have better capacity to meet long-term requirements and will work to improve its abilities to handle major disease outbreaks.

This includes zoonotic diseases, which can also pose a threat to human health. Nearly two-thirds of infectious diseases affecting humans originate from animals, including avian influenza and bovine tuberculosis.

APHA works to safeguard the UK’s livestock industry through its research into dangerous animal and plant diseases. The export of livestock and animal products is worth £16bn to the UK economy.

The laboratories in Weybridge are APHA’s primary facilities for tackling the spread of infectious diseases. APHA describes the facility as a critical national infrastructure and a global centre of expertise on animal diseases.

The department’s work is currently seeing it tackle the threats of avian influenza and bluetongue virus, which are spreading across the country. Biosecurity risks are expected to increase in the coming years as the changing climate increases pathways to disease spread.

Steve Reed, environment secretary, said: “We inherited laboratories at Weybridge in poor condition, reducing our ability to respond to animal disease outbreaks.

“Recognising the importance of protecting our farming and food sector in order to deliver growth across the UK, we are bolstering our national biosecurity and safeguarding the county from these diseases with a £200 million investment into our scientific capabilities.”

Jenny Stewart, APHA chief executive, said: “The work we do is world-leading, and this funding affirms the government’s commitment to protecting animal and plant health and will help us protect the economy from disease risk.”

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.